Disease · MONDO_0000675

pain agnosia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pain agnosia. Diseases, record MONDO_0000675. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000675

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pain agnosia; Open Targets
Open Targets ID: MONDO_0000675; Open Targets
Other names: agnosia for pain, analgesia; Open Targets
Disease Ontology: DOID:0060145; Disease Ontology
NCI Thesaurus: C125664; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 33 drugs, from TTD; Open Targets

Drugs33

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FENTANYL	CHEMBL596	Small molecule	Approval	TTD	3	2	2	Drugs and targets
MEPIVACAINE	CHEMBL1087	Small molecule	Approval	TTD	2	1	1	Drugs and targets
PHENACETIN	CHEMBL16073	Small molecule	Approval	TTD, at withdrawal	1	0	0	Drugs and targets
SALICIN	CHEMBL462997	Small molecule	Approval	TTD	1	0	0	Drugs and targets
SUFENTANIL	CHEMBL658	Small molecule	Approval	TTD	1	0	0	Drugs and targets
TETRAHYDROPALMATINE	CHEMBL487182	Small molecule	Approval	TTD	1	0	0	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MIDAZOLAM	CHEMBL655	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROMORPHONE HYDROCHLORIDE	CHEMBL1237055	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
NALBUPHINE HYDROCHLORIDE	CHEMBL1201132	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 33

See all 33 drugs

Targets40

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	7	Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets
GABRA1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 40

See all 40 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02250703	Intranasal Dexmedetomidine Premedication in Children	Phase 3	75	2017-07-07	Preoperative Sedation	DEXMEDETOMIDINE, MIDAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT06785571	The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial	Phase 2/3	204		Respiratory Insufficiency	HYDROMORPHONE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00137085	Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation	Not applicable	124		Fractures, Dislocations, Abscess, Anesthesia, Analgesia	FENTANYL, KETAMINE	Its record names the disease	ClinicalTrials.gov
NCT01981291	Duration of Sciatic Nerve Block After Injection of Local Anesthetic In or Around the Nerve	Phase 4	120		Orthopedic Surgical Procedures, Postoperative Pain	MEPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT05053763	The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg	Not applicable	120		Anesthesia	ALFENTANIL, REMIMAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT05865470	Age-dependent Effects of Smoked and Oral Delta-9-THC	Phase 1	103		Pain, Abuse, Drug, Intoxication; Cannabinoids	DRONABINOL	Its record names the disease	ClinicalTrials.gov
NCT06907277	Dexmedetomidine Enhancing the Recovery After Cardiac Surgery	Not applicable	75		Post-cardiac Surgery	DEXMEDETOMIDINE, FENTANYL, LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT07301970	Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients		45		Critical Illness, Pain	REMIFENTANIL	Its record names the disease	ClinicalTrials.gov
NCT04492813	Plasmatic Concentrations of Propofol and Remifentanil in Obese and Non Obese Patients.	Not applicable	40		General Anesthesia, Obesity	PROPOFOL, REMIFENTANIL	Its record names the disease	ClinicalTrials.gov
NCT02593370	Suprasacral Parallel Shift - Ultrasound/MR Image Fusion Guided Lumbosacral Plexus Block	Phase 1	26		Hip Fractures, Anesthesia Local, Pain, Perioperative	LIDOCAINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Midazolam vs Dexmedetomidine: serious adverse events	0 of 37	0 of 36	73	NCT02250703

Source Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24237879	RESULT	1	PubMed
22950484	RESULT	1	PubMed
22268591	RESULT	1	PubMed
18499600	RESULT	1	PubMed
15105196	RESULT	1	PubMed
42131816	DERIVED	1	PubMed
38745175	DERIVED	1	PubMed
31318038	DERIVED	1	PubMed
28396863	DERIVED	1	PubMed
18754820	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000675

GET https://conductscience.org/api/diseases/v1/MONDO_0000675/drugs?page=2

API reference For AI assistants